Chiron Investment Management LLC Invests $512,000 in Amgen Inc. (NASDAQ:AMGN)

Chiron Investment Management LLC bought a new stake in Amgen Inc. (NASDAQ:AMGN) in the 3rd quarter, according to its most recent filing with the SEC. The fund bought 1,590 shares of the medical research company’s stock, valued at approximately $512,000.

A number of other hedge funds have also recently added to or reduced their stakes in AMGN. Capital Performance Advisors LLP acquired a new position in shares of Amgen in the third quarter worth about $25,000. Strategic Financial Concepts LLC purchased a new position in shares of Amgen in the 2nd quarter valued at about $26,000. Legacy Investment Solutions LLC purchased a new position in Amgen during the third quarter worth approximately $29,000. Hershey Financial Advisers LLC acquired a new stake in Amgen in the second quarter valued at approximately $30,000. Finally, nVerses Capital LLC purchased a new stake in shares of Amgen in the second quarter valued at approximately $31,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Trading Down 0.7 %

Shares of Amgen stock opened at $275.75 on Wednesday. Amgen Inc. has a fifty-two week low of $257.80 and a fifty-two week high of $346.85. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The firm has a market capitalization of $148.22 billion, a price-to-earnings ratio of 35.31, a PEG ratio of 3.02 and a beta of 0.55. The stock has a 50 day moving average of $305.69 and a 200 day moving average of $315.66.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period last year, the company earned $4.96 EPS. As a group, research analysts predict that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.45%. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s payout ratio is 115.24%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on AMGN. Citigroup decreased their target price on Amgen from $335.00 to $310.00 in a research report on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Wolfe Research started coverage on shares of Amgen in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. Dbs Bank upgraded Amgen to a “strong-buy” rating in a research note on Monday, September 16th. Finally, William Blair restated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $319.68.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.